Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 38.01%.

  • Adma Biologics' EBITDA Margin rose 49300.0% to 38.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.19%, marking a year-over-year increase of 41700.0%. This contributed to the annual value of 32.59% for FY2024, which is 242100.0% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' EBITDA Margin is 38.01%, which was up 49300.0% from 35.08% recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' EBITDA Margin peaked at 38.01% during Q3 2025, and registered a low of 94.49% during Q1 2021.
  • In the last 5 years, Adma Biologics' EBITDA Margin had a median value of 0.79% in 2023 and averaged 6.12%.
  • As far as peak fluctuations go, Adma Biologics' EBITDA Margin surged by 1325000bps in 2021, and later tumbled by -14900bps in 2025.
  • Over the past 5 years, Adma Biologics' EBITDA Margin (Quarter) stood at 23.98% in 2021, then soared by 49bps to 12.12% in 2022, then skyrocketed by 259bps to 19.26% in 2023, then surged by 69bps to 32.6% in 2024, then increased by 17bps to 38.01% in 2025.
  • Its EBITDA Margin was 38.01% in Q3 2025, compared to 35.08% in Q2 2025 and 30.38% in Q1 2025.